Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $332
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated LGND | 0.00 |
Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:
LGND) with a Buy and raises the price target from $255 to $332.